BioScience Health Innovations, Inc.
NOTR
$9.01
-$0.99-9.90%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 100.99% | 198.13% | 452.81% | 759.44% | 635.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 100.99% | 198.13% | 452.81% | 759.44% | 635.11% |
| Cost of Revenue | 304.17% | 366.04% | 676.84% | 810.64% | 1,166.04% |
| Gross Profit | 43.34% | 164.94% | 417.33% | 750.72% | 556.94% |
| SG&A Expenses | 19.72% | 69.43% | 62.67% | 193.08% | 378.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.53% | 107.30% | 100.32% | 221.05% | 444.59% |
| Operating Income | 126.04% | 198.42% | 186.99% | 24.47% | -78.60% |
| Income Before Tax | 126.04% | 198.42% | 186.99% | 24.47% | 51.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 126.04% | 198.42% | 186.99% | 24.47% | 51.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 126.04% | 198.42% | 186.99% | 24.47% | 51.82% |
| EBIT | 126.04% | 198.42% | 186.99% | 24.47% | -78.60% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 122.22% | 192.86% | 185.71% | 74.51% | 89.16% |
| Normalized Basic EPS | 116.67% | 188.89% | 184.62% | 75.00% | 88.46% |
| EPS Diluted | 106.45% | 192.86% | 185.71% | 74.51% | 62.65% |
| Normalized Diluted EPS | 116.67% | 188.89% | 184.62% | 75.00% | 88.46% |
| Average Basic Shares Outstanding | 4.58% | 4.28% | 4.40% | 198.57% | 325.14% |
| Average Diluted Shares Outstanding | 8.70% | 4.28% | 4.40% | 198.57% | 325.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |